- Home
- PCRX vs RERE Comparison
PCRX vs RERE Comparison
Compare PCRX & RERE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCRX | RERE |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 972.6M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PCRX | RERE |
|---|---|---|
| Price | $22.77 | $4.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $30.25 | N/A |
| AVG Volume (30 Days) | 515.7K | ★ 633.0K |
| Earning Date | 04-30-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 2.27% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $6.78 | $25.70 |
| Revenue Next Year | $8.54 | $22.93 |
| P/E Ratio | $336.79 | ★ $34.57 |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $2.41 |
| 52 Week High | $27.64 | $6.47 |
Technical Indicators
Market Signals| Indicator | PCRX | RERE |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 40.35 |
| Support Level | $22.13 | $4.26 |
| Resistance Level | $24.20 | $4.37 |
| Average True Range (ATR) | 1.26 | 0.17 |
| MACD | -0.25 | 0.01 |
| Stochastic Oscillator | 8.81 | 6.67 |
Price Performance
Historical ComparisonAbout PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.